文献速递妇科产科

绝经前降低风险双侧输卵管卵巢切除术后12个月内抑郁与焦虑的前瞻性对照研究

What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
PubMed 文献 · Gynecol Oncol · 2021-02-11

该前瞻性对照观察研究纳入95例计划行RRBSO的绝经前女性和99例保留卵巢的绝经前女性,在基线、3、6、12个月评估抑郁和焦虑症状。RRBSO后3个月临床显著抑郁症状翻倍(14.5% vs 27.1%,p=0.010)并持续至12个月,焦虑症状近乎三倍(6.1% vs 17.7%,p=0.014)后于6个月平台、12个月回落至基线。RRBSO组慢性抑郁症状风险增加3.0倍(Wald 95%CI 1.27-7.26),新发抑郁风险增加2.3倍(95% Wald CI 1.08-5.13),新发焦虑风险增加2.0倍(Wald 95%CI 0.78-5.00)。

要点

  • RRBSO后3个月临床显著抑郁症状翻倍并持续至12个月。
  • RRBSO后3个月焦虑症状近乎三倍,6个月平台、12个月回落基线。
  • RRBSO组慢性抑郁风险增3.0倍、新发抑郁增2.3倍、新发焦虑增2.0倍。

核心结论

  • RRBSO导致临床显著抑郁和焦虑症状快速增加,且尽管使用激素治疗仍出现。

研究设计与样本

  • 前瞻性对照观察研究,纳入95例计划行RRBSO的绝经前女性和99例保留卵巢的绝经前女性,其中95%为人群水平卵巢癌风险。

主要发现

  • 基线症状及既往抑郁或焦虑史组间无差异。
  • RRBSO后3个月临床显著抑郁症状为27.1% vs 14.5%(p=0.010),并持续至12个月;对照组抑郁症状稳定。
  • RRBSO后3个月临床显著焦虑症状为17.7% vs 6.1%(p=0.014),6个月平台,12个月回落至基线。
  • RRBSO组慢性抑郁症状风险增加3.0倍(Wald 95%CI 1.27-7.26),新发抑郁风险增加2.3倍(95% Wald CI 1.08-5.13),新发焦虑风险增加2.0倍(Wald 95%CI 0.78-5.00)。
  • RRBSO后激素治疗使用者抑郁和焦虑略多于非使用者。

临床怎么用

  • 对计划行RRBSO的绝经前女性应告知术后抑郁和焦虑症状快速增加的风险。
  • RRBSO术后早期应监测抑郁和焦虑症状,即使患者使用激素治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Risk-reducing bilateral salpingo-oophorectomy (RRBSO) substantially reduces ovarian cancer risk in women with pathogenic gene variants and is generally recommended by age 34-45 years. Natural menopause is a vulnerable period for mood disturbance, but the risk of depression and anxiety in the first 12 months after RRBSO and potential modifying effect of hormone therapy are uncertain. METHODS: Prospective controlled observational study of 95 premenopausal women planning RRBSO and a Comparison group of 99 premenopausal women who retained their ovaries,- 95% of whom were at population level risk of ovarian cancer. Clinically significant symptoms of depression and anxiety were measured using standardised instruments at baseline, 3, 6 and 12 months. Chi-square tests and adjusted logistic regression models compared differences between groups. RESULTS: Baseline symptoms and previous depression or anxiety did not differ between groups. At 3 months after RRBSO clinically significant depressive symptoms were doubled (14.5% vs 27.1%, p = 0.010), which persisted at 12 months. Depressive symptoms were stable in comparisons. At 3 months after RRBSO, clinically significant anxiety symptoms almost trebled (6.1% vs 17.7%, p = 0.014) before plateauing at 6 months and returning to baseline at 12 months. Compared to comparisons, RRBSO participants were at 3.0-fold increased risk of chronic depressive symptoms (Wald 95% CI 1.27-7.26), 2.3-fold increased risk of incident depression (95% Wald CI 1.08-5.13) and 2.0-fold increase of incident anxiety (Wald 95% CI 0.78-5.00). Depression and anxiety were slightly more common in Hormone Therapy users after RRBSO vs non-users. CONCLUSIONS: RRBSO leads to a rapid increase in clinically significant depressive and anxiety symptoms despite Hormone Therapy use.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hickey M, Moss KM, Brand A, et al. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol. 2021. PMID: 33583580. doi:10.1016/j.ygyno.2021.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。